Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C_ASCENT: IFN-Free HCV Therapy in HIV Coinfection
NCT02194998Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2015
- Primary completion
- May 2018
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label trial of paritaprevir, ritonavir, ombitasvir and dasabuvir in hepatitis C (HCV) (4 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Sustained Virologic Response at 12 Weeks, Serious Adverse Events and 4 more. Started Sep 2015; status: terminated.
02
Drugs
paritaprevirritonavirombitasvirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02194998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194998.